MIRM vs TVTX
MIRM: Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative, minimally-absorbed therapies for rare cholestatic liver diseases. TVTX: A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need.
Side-by-side fundamentals
| Metric | MIRM | TVTX | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $96.72 | $65.22 | |
| Market cap as of 2026-08-24 | $6.3B | $6.1B | |
| PEG as of 2026-08-24 | -0.01 | 1.04 | MIRM lower |
| Net margin as of 2026-08-24 | -139.2% | -7.3% | TVTX higher |
| Gross margin as of 2026-08-24 | +81.7% | +98.6% | TVTX higher |
| Operating margin as of 2026-08-24 | -136.8% | -6.8% | TVTX higher |
| ROE as of 2026-08-24 | -289.3% | -55.8% | TVTX higher |
| ROA as of 2026-08-24 | -96.5% | -7.0% | TVTX higher |
| Debt / equity as of 2026-08-24 | 1.28 | 24.58 | MIRM lower |
| Revenue growth (YoY) as of 2026-08-24 | +44.0% | +77.1% | TVTX higher |
| Revenue CAGR (3y) SEC XBRL | +89.1% | +64.9% | MIRM higher |
| Beta as of 2026-08-24 | 0.83 | 1.22 | |
| 1-year return as of 2026-08-24 close | +35.2% | +264.0% | TVTX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.